Navigation Links
China Medical Technologies Reports Second Fiscal Quarter Financial Results
Date:11/19/2009

f the non-GAAP financial measures to the most directly comparable GAAP financial measures, please see the financial information included with this earnings announcement.

Conference Call

The Company's management team will host a conference call at 8:00a.m. U.S. Eastern Time on November 19, 2009 (or 9:00p.m. Beijing/Hong Kong time on the same date) to discuss the results following this earnings announcement.

    The dial-in details for the live conference call are as follows:

    U.S. Toll Free Number 1-800-435-1398
    International dial-in number 1-617-614-4078
    Passcode CMEDCALL

A live webcast of the conference call will be available on http://ir.chinameditech.com .

A replay of this webcast will be available for one month on this website.

A telephone replay of the call will be available after the conclusion of the conference call through 10:00a.m. U.S. Eastern Time on November 20, 2009.

    The dial-in details for the replay are as follows:

    U.S. Toll Free Number 1-888-286-8010
    International dial in numbers 1-617-801-6888
    Passcode 45921509

About China Medical Technologies, Inc.

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products using Enhanced Chemiluminescence (ECLIA) technology, Fluorescent in situ Hybridization (FISH) technology and Surface Plasmon Resonance (SPR) technology to detect and monitor various diseases and disorders. For more information, please visit http://www.chinameditech.com .

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of
'/>"/>

SOURCE China Medical Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009
2. Jiangbo Pharmaceuticals to Present at Brean Murray, Carret 2009 China Growth Conference
3. Novartis to Acquire Majority Stake in Hard to Treat Diseases (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million
4. Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin
5. HUYA Bioscience International Establishes Strategic Partnership with School of Medicine and Pharmacy, Ocean University of China
6. China Nepstar Enters Into Strategic Cooperation Agreement with ATMU to Install More Than 1,000 ATMs in Nepstar Stores
7. China Medical Technologies to Announce Unaudited Financial Results for the Second Fiscal Quarter Ended September 30, 2009 on November 19, 2009
8. China Pharma Holdings, Inc. to Report Third Quarter 2009 Financial Results on November 12, 2009
9. Perot Systems Announces Strategic Alliance With China Telecom
10. China Medicine Corporations Levocarnitine Dried Powder Injection Was Registered with the Ministry of Health of Pakistan
11. Niusule Launches Niusule Gummy Bears in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... Spending time online has the potential to ward off ... according to research published online in The ... Sciences . In the article " Internet Use ... States: A Longitudinal Analysis ," the authors report that ... by 33 percent among their study sample. , ...
(Date:4/17/2014)... It,s not uncommon these days to find a colored ribbon ... signify breast cancer. But what color ribbon does one think ... the designated color, for many suffering from the disease, black ... State University study consisting of lung cancer patients, primarily smokers ... shedding more light on the stigma often felt by these ...
(Date:4/17/2014)... 40 years away from a food shortage that will ... a top scientist at the U.S. Agency for International ... production will be limited on a global scale by ... Fred Davies, senior science advisor for the agency,s bureau ... destabilizing by 2050 as energy issues are today.", Davies, ...
(Date:4/17/2014)... TORONTO, April 17, 2014 Giving patients adrenaline after they ... not increase their prospects of surviving long-term, according to ... vast number of patients who have a cardiac arrest ... treating cardiac arrest for decades," said Dr. Steve Lin, ... Michael,s. "Yet, despite advances in medical treatment, long-term survival ...
(Date:4/17/2014)... called for more research to be carried out ... sub-Saharan Africa. In a paper in The ... working with colleagues in the department of Parasitology ... Cleveland Ohio, University of Cambridge and the Royal ... joint burden of HIV/AIDS and schistosomiasis of children, ...
Breaking Medicine News(10 mins):Health News:Internet use may cut retirees' depression 2Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:More research called for into HIV and schistosomiasis coinfection in African children 2
... , AVENTURA, Fla., Dec. 21 Cinergy ... benefit programs for the consumer market, expressed its concern for the ... this morning. , "While the Senate and House healthcare bills are ... step towards expanding access to affordable health coverage for all Americans," ...
... on edibles that will signal fullness just by chewing ... possible to create foods with hunger-suppressing aromas that would offer ... scientists say. , Researchers have long attempted to develop foods ... until recently, have focused on the effects of food in ...
... powerful results in mice and people, researchers say , ... a protein that may be involved in the development ... to new drugs to fight this growing worldwide scourge. ... inhibiting this pathway worked to block pain associated with ...
... ... schedules have been finalized for the ,second annual Dr. Alec Kessler Memorial High School ... Center., , ... (Vocus) December 21, 2009 -- The teams and the tournament schedules have been finalized for ...
... , BOCA RATON, Fla., Dec. 21 Flipping ... system for children and adults, has teamed up with Fisher ... to the retail value of $10,000 - to the children ... In an effort to make the holidays a bit ...
... , , AARP PENNSYLVANIA KEY VOTE NEWS ALERT , ATTENTION ... on key issues throughout the 111th Congress, and informing its nearly ... these key votes. , HARRISBURG, Pa., Dec. 21 The U.S. ... that will begin to bring needed relief to millions of Americans ...
Cached Medicine News:Health News:Cinergy Health Commentary on Senate Healthcare Vote 2Health News:Diabetes Insight Could Lead to Better Treatments 2Health News:Teams And Tournament Schedule Finalized For The Dr. Alec Kessler Memorial High School Basketball Invitational December 28-30, 2009 2Health News:Teams And Tournament Schedule Finalized For The Dr. Alec Kessler Memorial High School Basketball Invitational December 28-30, 2009 3Health News:Flipping for Phonics(TM) Helps Spread Cheer To Military Families In Fisher Houses(R) This Holiday Season 2Health News:Flipping for Phonics(TM) Helps Spread Cheer To Military Families In Fisher Houses(R) This Holiday Season 3Health News:AARP Applauds Senate for Moving Health Care Reform Forward 2Health News:AARP Applauds Senate for Moving Health Care Reform Forward 3
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Presented Along With Updated Phase 1 Colorectal Cancer ... Data at ... CHICAGO, June 1 /PRNewswire-FirstCall/,-- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ... results,from its ongoing randomized Phase 2 clinical trial in patients ...
... Greater Than 50% Response Rate and 100% Disease Control Rate Observed ... Patients with Medullary Thyroid Cancer, ... encouraging new data from an ongoing phase 1 clinical trial of,XL184, ... with advanced malignancies. The maximum tolerated dose (MTD) for,XL184 has been ...
Cached Medicine Technology:Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 2Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 3Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 4Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 2Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 3Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 4Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 6
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: